title: Hypoxia imaging of uterine cervix carcinoma with (18)F-FETNIM PET/CT.
abstract: OBJECTIVE
  Our aims were to assess the feasibility of imaging hypoxia in cervical carcinoma with (18)F-fluoroerythronitroimidazole ((18)F-FETNIM) and to compare (18)F-FETNIM uptake with metabolic uptake of (18)F-FDG.
  
  
  METHODS
  We included 16 patients with cervical carcinoma. After imaging with FDG, (18)F-FETNIM PET/CT was performed and tumor-to-muscle (T/M) ratio uptake was assessed. (18)F- FETNIM uptake was correlated to FDG uptake and osteopontin (OPN), a marker of hypoxia, and patients' outcomes.
  
  
  RESULTS
  All tumors were detected by (18)F-FDG PET. (18)F-FETNIM T/M ratios ranged from 1.3 to 5.4. There was no significant correlation between (18)F-FETNIM and (18)F-FDG uptake. High (18)F-FETNIM uptake (T/M > 3.2) was associated with reduced progression-free survival (log-rank = 0.002) and overall survival (log-rank = 0.02). Osteopontin ranged from 39 to 662 μg/L (median, 102.5 μg/L). Patients with OPN greater than 144 μg/L had reduced progression-free survival compared with those with OPN less than 144 μg/L (log-rank = 0.03). We found no significant correlation between (18)F-FETNIM uptake and OPN blood levels.
  
  
  CONCLUSIONS
  Our preliminary results showed that a high uptake of (18)F-FETNIM was associated with a worse progression-free and overall survival.
authors.affiliation: Departments of Nuclear Medicine, Hospital Saint Louis APHP Paris, France. laetitia.vercellino@sls.aphp.fr
authors.forename: Laetitia
authors.initials: L
authors.lastname: Vercellino
authors.forename: David
authors.initials: D
authors.lastname: Groheux
authors.forename: Anne
authors.initials: A
authors.lastname: Thoury
authors.forename: Marc
authors.initials: M
authors.lastname: Delord
authors.forename: Marie-Hélène
authors.initials: MH
authors.lastname: Schlageter
authors.forename: Yann
authors.initials: Y
authors.lastname: Delpech
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Barré
authors.forename: Valérie
authors.initials: V
authors.lastname: Baruch-Hennequin
authors.forename: Perrine
authors.initials: P
authors.lastname: Tylski
authors.forename: Laurence
authors.initials: L
authors.lastname: Homyrda
authors.forename: Francine
authors.initials: F
authors.lastname: Walker
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Barranger
authors.forename: Elif
authors.initials: E
authors.lastname: Hindié
mesh_terms: D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D000860:Hypoxia / Q000000981:diagnostic imaging*; D021621:Imaging, Three-Dimensional; D008875:Middle Aged; D064847:Multimodal Imaging; D009593:Nitroimidazoles; D049268:Positron-Emission Tomography; D014057:Tomography, X-Ray Computed; D002583:Uterine Cervical Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology
chemical_list: D009593:Nitroimidazoles; C092114:fluoroerythronitroimidazole; D019788:Fluorodeoxyglucose F18